Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Immunol Immunother ; 56(5): 649-58, 2007 May.
Article in English | MEDLINE | ID: mdl-16947020

ABSTRACT

Cancer therapies, which deliver a rapidly induced massive tumor tissue injury, such as photodynamic therapy (PDT), provoke a strong host response raised for dealing with the inflicted local trauma. Activated complement system was identified as an important element of host response elicited by tumor PDT. The expression of genes encoding complement proteins C3, C5, and C9 was studied following tumor PDT mediated by photosensitizer Photofrin using mouse Lewis lung carcinoma (LLC) model. Treated tumors and the livers of host mice were collected at different times after PDT and the expression of the investigated genes was analyzed by RT-PCR. The results show a significant up-regulation of C3, C5, and C9 genes in PDT-treated tumors at 24 h after therapy, while no significant increase in the expression of these genes was found in the liver tissues. The expression of C3, C5, and C9 genes also became up-regulated in untreated tumor-associated macrophages (TAMs) co-incubated in vitro with PDT-treated LLC cells. This effect was abolished or drastically reduced in the presence of antibodies blocking heat shock protein 70 (HSP70), Toll-like receptor (TLR) 2 and TLR4, and specific peptide inhibitors of TIRAP adapter protein and transcription factor NF-kappaB. The presented study reveals that complement genes C3, C5, and C9 become up-regulated in tumors treated by PDT, but not in the host's liver. Tumor-localized up-regulation of these genes can be largely attributed to monocytes/macrophages invading the treated lesion after PDT. This effect appears to be induced by the recognition of danger signals from PDT-treated tumor cells such as HSP70 by TAMs that involve the TLR2- and TLR4-triggered signal transduction pathways leading to the activation of NF-kappaB.


Subject(s)
Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/genetics , Complement C3/genetics , Complement C5/genetics , Complement C9/genetics , Photochemotherapy , Animals , Complement C3/metabolism , Complement C5/metabolism , Complement C9/metabolism , Dihematoporphyrin Ether/therapeutic use , Gene Expression/drug effects , Gene Expression Profiling , HSP70 Heat-Shock Proteins/metabolism , Macrophages/metabolism , Mice , Photosensitizing Agents/therapeutic use , Reverse Transcriptase Polymerase Chain Reaction , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism
2.
Int Immunopharmacol ; 6(8): 1259-66, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16782538

ABSTRACT

Photodynamic therapy (PDT) inflicts tumor tissue injury that is experienced by the host as a local trauma. This provokes a strong host response with pronounced neutrophilia as one of its manifestations. Mouse FsaR fibrosarcoma model was used for investigating photodynamic therapy (PDT)-induced neutrophilia and its link to the acute phase response. Compared to normal mice, the extent of neutrophilia induced following Photofrin-based tumor PDT in adrenalectomized host mice was less pronounced revealing the elicited engagement of the adrenal-pituitary axis, which is one of the principal characteristics of the acute phase response. Neutrophilia was demonstrated after tumor-localized PDT even in the host mice previously depleted of circulating neutrophils. The rise in serum levels of complement C3 protein, which is an acute phase reactant and a principal mediator of tumor PDT-induced neutrophilia, occurred at the post PDT time period when the neutrophilia was largely resolved. However, the activation of complement system (assessed by the standard erythrocyte hemolysis assay) peaked already at 6 h after PDT and correlated with the time kinetics of PDT-induced neutrophilia. The findings of this study uncover the link between tumor PDT-induced neutrophilia and key acute phase response manifestations, the activation of adrenal-pituitary axis and the expression of a complement C3 protein (major acute phase reactant).


Subject(s)
Acute-Phase Reaction/immunology , Fibrosarcoma/drug therapy , Neoplasms, Experimental/drug therapy , Neutrophils/drug effects , Photochemotherapy/adverse effects , Acute-Phase Reaction/blood , Acute-Phase Reaction/etiology , Adrenalectomy , Animals , Bone Marrow/drug effects , Bone Marrow/immunology , Complement Activation/drug effects , Complement Activation/immunology , Complement C3/metabolism , Dihematoporphyrin Ether/administration & dosage , Dihematoporphyrin Ether/therapeutic use , Liver/drug effects , Liver/immunology , Lung/drug effects , Lung/immunology , Mice , Mice, Inbred C3H , Mice, Inbred Strains , Neutropenia/blood , Neutropenia/etiology , Neutropenia/immunology , Neutrophils/metabolism , Neutrophils/pathology , Photochemotherapy/methods , Spleen/drug effects , Spleen/immunology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...